Document Detail

Injectable in situ forming drug delivery system for cancer chemotherapy using a novel tissue adhesive: characterization and in vitro evaluation.
MedLine Citation:
PMID:  17240124     Owner:  NLM     Status:  MEDLINE    
Injectable polymers that are biocompatible and biodegradable are important biomaterials for drug delivery system (DDS) and tissue engineering. We have already developed novel tissue adhesives consisting of biomacromolecules and organic acid derivatives with active ester groups. The resulting tissue adhesive forms in situ as a gel and has high bonding strength for living tissue as well as it has good biocompatibility and biodegradability. Here, we report on the physicochemical properties and in vitro evaluation of this novel tissue adhesive consisting of human serum albumin (HSA) and tartaric acid derivative (TAD) containing doxorubicin hydrochloride (DOX). The results of the measurement of physicochemical characteristics indicate that the gelation time and gel strength of HSA-TAD gels can be controlled according to the material composition. The bonding strength of HSA-TAD adhesives was found to be sufficient to adhere at focus and to correspond with the cross-linking density of HSA-TAD gels. Furthermore, the release of DOX from HSA-TAD gels was sustained for approximately 100 h in an in vitro evaluation. The novel tissue adhesive, therefore, is expected to be applicable for use as an injectable in situ forming DDS.
Sachiro Kakinoki; Tetsushi Taguchi; Hirofumi Saito; Junzo Tanaka; Tetsuya Tateishi
Related Documents :
18929274 - Three-dimensional quantification of adhesive remnants on teeth after debonding.
19632714 - Influence of the hydrostatic pulpal pressure on droplets formation in current etch-and-...
323264 - Studies on dental self-curing resins. xv. application of nitrene to reactive adhesive w...
14509094 - Evaluating dentin bonding agents: an update.
16386984 - Markers of inflammation, vascular endothelial dysfunction, and age-related cataract.
18405174 - Vasculopathy and vasculitis in systemic lupus erythematosus.
Publication Detail:
Type:  Journal Article     Date:  2006-12-02
Journal Detail:
Title:  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V     Volume:  66     ISSN:  0939-6411     ISO Abbreviation:  Eur J Pharm Biopharm     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-05-22     Completed Date:  2007-08-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9109778     Medline TA:  Eur J Pharm Biopharm     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  383-90     Citation Subset:  IM    
Biomaterials Center, National Institute for Materials Science, Ibaraki, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Doxorubicin / administration & dosage*
Drug Delivery Systems*
Neoplasms / drug therapy*
Serum Albumin / administration & dosage
Tissue Adhesives / administration & dosage*
Reg. No./Substance:
0/Gels; 0/Serum Albumin; 0/Tissue Adhesives; 23214-92-8/Doxorubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  New MultiPEG-conjugated theophylline derivatives: synthesis and pharmacological evaluations.
Next Document:  Paclitaxel/beta-cyclodextrin complexes for hyperthermic peritoneal perfusion - formulation and stabi...